Three-year Extended Follow-up of the 2NN Study: Nevirapine versus Efavirenz
Three-year Extended Follow-up of the 2NN Study: Nevirapine versus Efavirenz
Francisco Blanco
NULL
*Correspondence: Francisco Blanco, Email not available
Abstract
Given their long plasma half-lives, potency againstHIV, low pill burdens, and ability to be safely combinedwith other commonly used medications, theNNRTI nevirapine and efavirenz are widely used incombination antiretroviral therapies. Some prior cohortstudies among antiretroviral-naive patients havesuggested that efavirenz might be superior to nevirapinein terms of efficacy.
